STOCK TITAN

Radnostix, Inc. Reports FY2026 3rd Quarter and Nine Months Results - Theranostics Sales Up 15% Year-over-Year, Signs Agreement to Sell Fluorine Products/DUF6 Assets to Nano Nuclear Energy, Submits Type II DMF for Sodium Iodide I-131 API

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Radnostix (OTCQB: INIS) reported third-quarter revenue of $2.57 million, with lower Cobalt and Calibration sales outweighing Theranostics growth. Revenue fell 22% year over year, while net loss widened to $842,242 from $203,601. Nine-month revenue fell 25% to $7.62 million, and net loss reached $3,072,325 versus $477,080. Theranostics quarterly sales rose 15% to $1.71 million.

Radnostix agreed to sell its Fluorine Products/DUF6 assets to Nano Nuclear Energy and subsidiary HALEU Energy Fuel for $13.5 million: $9.5 million cash and $4 million in restricted NNE shares. Closing requires NRC license-transfer approval and site rights. Approximately $1.2 million of contracted Cobalt deliveries shifted to Q1 2027, pending NRC amendments. In October, Radnostix submitted a Type II drug master file for sodium iodide I-131 active pharmaceutical ingredient to support a customer's drug application and obtained a $1.0 million revolving credit line.

Loading...
Loading translation...
11 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 23 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major pointFluorine Products/DUF6 sale agreement provides $13.5 million consideration: $9.5 million cash and $4 million restricted NNE shares. 66% of market cap
  • Moderate pointTheranostics Q3 revenue rose 15% year over year to $1.71 million, reflecting customer growth.
  • Moderate pointOctober revolving credit facility provides $1.0 million of additional working-capital and liquidity capacity. 4.9% of market cap
  • Minor pointTheranostics Q3 segment income increased to $0.67 million from $0.63 million; gross margin remained approximately 67%.
  • Minor pointSodium iodide I-131 Type II drug master file submitted in October to support a customer's drug application.
6 minor points
  • Minor pointBoth voluntary recalls were fully executed, with required documentation submitted to the FDA in June 2026.
  • Minor pointGadolinium-153 supply secured; commercial Calibration & Reference batches shipped in November 2026 after a multi-year global outage.
  • Minor pointCalibration & Reference Products received Health Canada registration approvals for multiple geometries during and after the quarter.
  • Minor point. Forward-looking: it has not happened yet and may not happen.EasyFill rollout is targeted for Q1 2027; RadVent commercialization is expected to begin that quarter.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Acquired Lara and Ellexa assets are planned for marketing under Lara Detection.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Management plans to clear Calibration backlog and expand Health Canada registrations, subject to supplier deliveries.

Negative

  • Moderate pointQ3 revenue fell 22% to $2,571,035; nine-month revenue fell 25% to $7,621,744 year over year.
  • Moderate pointQ3 net loss widened to $842,242 from $203,601; nine-month loss widened to $3,072,325 from $477,080.
  • Moderate pointCash and equivalents declined to $0.71 million at September 30, 2026, from $1.70 million at December 31, 2025.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Approximately $1.2 million of contracted Cobalt deliveries moved from second-half 2026 to Q1 2027, pending NRC amendments. 5.9% of market cap
  • Moderate pointCalibration & Reference revenue fell 23% to $0.74 million in Q3 and 19% to $2.68 million over nine months.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Cobalt-57 supply interruption reduced Q3 sales by an estimated $250,000, leaving approximately $300,000 backlog and possible Q4 disruption. 1.2% of market cap
  • Moderate pointTheranostics nine-month revenue fell 19% to $4.18 million, reflecting estimated $850,000 first-half recall-related capsule revenue losses. 4.2% of market cap
  • Moderate pointNine-month gross profit fell 34% to $4,024,398; margin declined to 53% from 60%, largely reflecting recalls.
15 minor points
  • Minor pointDUF6 sale remains conditional on NRC license-transfer approval and NNE securing ownership or leasehold rights to the site.
  • Minor pointCobalt revenue fell 88% to $0.09 million in Q3 and 61% to $0.60 million over nine months.
  • Minor pointQ3 gross profit fell 22% to $1,514,215, despite an unchanged 59% gross margin.
  • Minor pointOperating expenses rose 8% to $2,297,254 in Q3 and 7% to $6,951,718 over nine months.
  • Minor pointOperating loss widened to $783,039 from $181,414 in Q3 and $2,927,320 from $381,271 over nine months.
  • Minor pointOther expense increased to $59,203 from $22,187 in Q3 and $145,005 from $95,809 over nine months.
  • Minor pointMedical Devices revenue fell 44% to $0.04 million in Q3 and 6% to $0.17 million over nine months.
  • Minor pointFluorine Products generated no revenue in either period; Q3 segment expenses were $64,457, including sale-related legal costs.
  • Minor pointCredit facility has a 12-month term at prime, collateral requirements and borrowing limits tied to eligible receivables and inventory.
  • Minor pointFDA formal recall close-out remains pending; the company also requested close-out of its April 2025 inspection.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Drug master file submission faces FDA review and potential additional-information requests, as anticipated by Radnostix.
  • Minor pointEBITDA, earnings before interest, taxes, depreciation and amortization, fell to negative $671,291 in Q3 from negative $36,582.
  • Minor pointNine-month EBITDA fell to negative $2,544,003 from positive $14,985.
  • Minor pointAdjusted EBITDA, also excluding stock compensation, fell to negative $552,942 in Q3 from negative $7,015.
  • Minor pointNine-month adjusted EBITDA fell to negative $2,061,950 from positive $110,349.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

IDAHO FALLS, Idaho, Nov. 16, 2026 /PRNewswire/ -- Radnostix, Inc. (formerly International Isotopes Inc.) (OTCQB: INIS) ("Radnostix" or the "Company"), a manufacturer of radioisotope-focused technologies for medical, industrial, and research applications, today announced its financial results for the third quarter and nine months ended September 30, 2026 and the filing of its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission.

Third Quarter and Nine Months 2026 Financial and Operational Summary

  • Total revenue for the three months ended September 30, 2026 was $2.57 million, a 22% decrease from $3.28 million in the prior-year period. Revenue for the nine months ended September 30, 2026 was $7.62 million, down 25% from $10.17 million in the first nine months of 2025. The third-quarter decline was driven primarily by delays in large Cobalt Products contracts, which are awaiting NRC amendments to the Company's registered sealed source devices, and lower Calibration & Reference Products sales due to a global interruption of cobalt-57 raw material supply, partially offset by a 15% increase in Theranostics Products sales. The nine-month decline also reflects the additional effects of the two voluntary product recalls initiated in the first quarter and the first-quarter Cobalt hot-cell shutdown.
  • Gross profit for the quarter was $1.51 million (59% margin) compared with $1.94 million (59% margin) in Q3 2025. Nine-month gross profit was $4.02 million (53% margin) versus $6.11 million (60% margin) in the prior-year period, stemming largely from the two voluntary Theranostics Product recalls.
  • Total operating expenses for the quarter were $2.30 million, up 8% from $2.12 million in Q3 2025, primarily reflecting higher professional services and license costs and increased Medical Devices development activity. Nine-month operating expenses were $6.95 million, up 7% from $6.49 million.
  • Net loss for the quarter was $0.84 million compared with $0.20 million in Q3 2025. Nine-month net loss was $3.07 million versus $0.48 million in the first nine months of 2025. Cash and cash equivalents were $0.71 million at September 30, 2026, compared with $1.70 million at December 31, 2025. In addition, the Company held $1.53 million of restricted cash supporting its NRC financial assurance.
  • In October 2026, the Company entered into a $1.0 million revolving line of credit with Bank of Commerce to provide additional working capital and liquidity. The facility has a 12-month term and bears interest at the prime rate. Borrowings limits under the facility are subject to eligible accounts receivable and inventory and are secured by the Company's accounts receivable, inventory, and equipment.

Shahe Bagerdjian, President and Chief Executive Officer, commented: "The third quarter showed the recovery of our core Theranostics business, with volumes restored in July and revenue up 15% over last year, and we took an important step to support a customer's NDA with our Type II DMF submission for Sodium Iodide I-131 API. Our Cobalt and Calibration & Reference results were held back by contract timing tied to NRC sealed source amendments and by a global cobalt-57 supply interruption, but we have since begun shipping Gd-153 products for the first time since the global outage. The agreement to sell our Fluorine Products/DUF6 assets to Nano Nuclear Energy, which remains subject to NRC approval and other closing conditions, would allow us to focus on our core radioisotope and medical device businesses. We are still focused on developing our medical devices and building stronger OEM relationships with camera companies for our Calibration & Reference products. Our priorities for the fourth quarter and into 2027 are clear: grow core revenues, convert our Cobalt and Calibration & Reference Products backlog, finalize launch of our Medical Devices products, and control costs."

Segment Highlights

  • Theranostics Products:
    • Q3 revenue of $1.71 million (up 15% year-over-year) and nine-month revenue of $4.18 million (down 19%). Segment income was $0.67 million in the quarter compared with $0.63 million in Q3 2025, with gross margin of approximately 67% in both periods. The three-month increase reflects growth in customers compared to prior year. The nine-month decline reflects lost capsule-related revenue of an estimated $850,000 during the first half of the year as a result of the voluntary recalls.
    • FDA Actions: Both voluntary recalls have been fully executed and all required documentation was submitted to the FDA in June 2026; the Company is awaiting formal recall close-out. A request for close-out of the April 2025 FDA Form 483 inspection was submitted by the Company.
    • Type II Drug Master File: In October 2026, the Company submitted a Type II Drug Master File (DMF) to the FDA for Sodium Iodide I-131 active pharmaceutical ingredient (API) in support of a customer's efforts to gain approval of its own New Drug Application. The Company anticipates a period of FDA review and potential requests for additional information.
  • Calibration & Reference Products:
    • Q3 revenue of $0.74 million (down 23%) and nine-month revenue of $2.68 million (down 19%). A global interruption of cobalt-57 raw material supply beginning in July 2026 reduced third-quarter sales by an estimated $250,000, and the Company had a backlog of approximately $300,000; prior-year results also included catch-up demand following the 2024 cobalt-57 shortage. The outage may also affect fourth-quarter cobalt-57 product sales if global suppliers are unable to catch up on deliveries.
    • Company secured a supply of gadolinium-153, after a multi-year global outage and shipped commercial batches of Gd-153 Calibration & Reference Products in November 2026.
    • The Company received Health Canada approvals for registration of multiple Calibration & Reference Products geometries both during the quarter and subsequently.
  • Medical Devices:
    • Q3 revenue of $0.04 million (down 44%) and nine-month revenue of $0.17 million (down 6%), all from third-party products.
    • The Company plans to market the Lara and Ellexa assets acquired from Lucerno Dynamics in June 2026 under a Lara Detection brand. The EasyFill Iodine Encapsulation System is targeted for a Q1 2027 roll-out, and RadVent products are expected to begin commercialization in Q1 2027.
  • Cobalt Products: Q3 revenue of $0.09 million (down 88%) and nine-month revenue of $0.60 million (down 61%). The third-quarter decrease was due to delays in large Cobalt contracts that are awaiting NRC amendments to the Company's registered sealed source devices; these contracts are projected to be executed in the first quarter of 2027. As a result, delivery dates for the approximately $1.2 million of contracted Cobalt sales that the Company previously announced for the second half of 2026 have moved to the first quarter of 2027. Nine-month results also reflect the first-quarter shutdown to repair the process hot cells.
  • Fluorine Products:
    • No revenue in either period. Segment expenses were $64,457 in the quarter, including legal expense related to the DUF6 Sale.
    • On September 28, 2026, the Company entered into an Asset Purchase Agreement with Nano Nuclear Energy Inc. ("NNE") and its wholly owned subsidiary, HALEU Energy Fuel Inc., to sell all of the assets of the Company's Fluorine Products segment, mainly assets related to the depleted uranium de-conversion and fluorine extraction plant previously planned for Lea County, New Mexico (the "DUF6 Sale"). Aggregate consideration is $13.5 million, consisting of $9.5 million in cash and $4 million of restricted shares of NNE common stock. Closing is subject to customary and other conditions, including NRC approval of the license transfer and NNE acquiring fee simple title to, or a valid leasehold interest in, the project site in Lea County. There can be no assurance that the DUF6 Sale will close. The license transfer application was submitted to the NRC on October 22, 2026 - public on NRC ADAMS, ML26296A222.

2026 Outlook and Focus Areas
Management's priorities for the remainder of 2026 and into 2027 center on:

  • Closing the DUF6 Sale
  • Clearing the cobalt-57 backlog and capturing Gd-153 catch-up demand, subject to supplier deliveries, and expanding Health Canada registrations.
  • Executing delayed Cobalt contracts, projected for the first quarter of 2027, subject to NRC sealed source device amendments.
  • Sustaining Theranostics growth following the completion of recall-related remediation, and supporting our customer's NDA through the Type II DMF.
  • Advancing Medical Devices commercialization of EasyFill, RadVent, and Lara Detection products
  • Disciplined cost management and working-capital focus.

Three Months Ended September 30,


Nine Months Ended September 30,


2026

2025

$ Change

%
Change


2026

2025

$ Change

%
Change

Sale of Product

$2,571,035

$3,277,816

($706,781)

-22 %


$7,621,744

$10,172,036

($2,550,292)

-25 %

Gross Profit

1,514,215

1,940,019

(425,804)

-22 %


4,024,398

6,113,615

(2,089,217)

-34 %

Total Operating Expense

2,297,254

2,121,433

175,821

8 %


6,951,718

6,494,886

456,832

7 %

Op. Loss Before Other
Exp.

(783,039)

(181,414)

(601,625)

332 %


(2,927,320)

(381,271)

(2,546,049)

668 %

Other Expense

(59,203)

(22,187)

(37,016)

167 %


(145,005)

(95,809)

(49,196)

51 %

Net Loss

($842,242)

($203,601)

($638,641)

314 %


($3,072,325)

($477,080)

($2,595,245)

544 %

Basic EPS (Loss)

–

–




(0.01)

–



Net Loss/Share (Diluted)

–

–




(0.01)

–



Wtd. Avg. Shares (Basic)

531,418,649

528,088,472




529,664,465

526,568,064



Wtd. Avg. Shares
(Diluted)

531,418,649

528,088,472




529,664,465

526,568,064



 


Three months ended September 30,


Nine months ended September 30,


2026

2025

$ Change

%
Change


2026

2025

$ Change

%
Change

Net Loss

($842,242)

($203,601)

($638,641)

314 %


($3,072,325)

($477,080)

($2,595,245)

544 %

Interest expense, net

72,177

66,301

5,876

9 %


212,275

192,367

19,908

10 %

Provision for income taxes

—

—

—

—


—

—

—

—

Depreciation and
amortization

98,774

100,718

(1,944)

-2 %


316,047

299,698

16,349

5 %

EBITDA

(671,291)

(36,582)

(634,709)

1735 %


(2,544,003)

14,985

(2,558,988)

-17077 %

Non-cash stock-based
compensation

118,350

29,568

88,782

300 %


482,053

95,364

386,689

405 %

Adjusted EBITDA

($552,942)

($7,015)

($545,927)

7782 %


($2,061,950)

$110,349

($2,172,299)

-1969 %

About Radnostix (formerly International Isotopes Inc.):  Radnostix, Inc. (formerly International Isotopes Inc.) (INIS), established in 1995, with its headquarters in Idaho Falls, ID, USA, manufactures a wide range of radioisotope-focused products. Radnostix manufactures and supplies generic sodium iodide I-131 radio-pharmaceutical drug product for hyperthyroidism and thyroid cancer. Radnostix provides contract manufacturing of various drug products as well as radioisotope API supply for 3rd party theranostics clients. Radnostix manufactures and distributes a complete line of calibration and reference standards for nuclear pharmacies and SPECT/PET imaging systems as well as industrial calibration standards under its RadQual brand. Radnostix also manufactures high activity sealed sources for industrial, medical, and defense applications. Radnostix is developing a portfolio of medical devices for use with diagnostic and therapeutic radiopharmaceutical applications, including our brands EasyFill™, RadVent™, and Lara Detection™. For more information, visit www.radnostix.com.

Non-GAAP Financial Measures
This press release contains financial measures that do not comply with U.S. generally accepted accounting principles ("GAAP"), such as EBITDA and Adjusted EBITDA. EBITDA is defined as net income (loss) plus interest expense, net, income taxes, and depreciation and amortization. Adjusted EBITDA is defined as EBITDA further adjusted to exclude non-cash stock-based compensation. These non-GAAP financial measures are supplemental measures to our results of operations as reported under GAAP. Our management uses these measures to better analyze our financial results and business operations. In management's opinion, these non-GAAP measures are useful to investors and other users of our financial statements by providing greater transparency into the ongoing operating performance of the Company. Such measures should not be considered alternatives to net income (loss) or any other performance measures derived in accordance with GAAP. The Company's measurement of EBITDA and Adjusted EBITDA may not be comparable to similar measures of other companies as they are not performance measures calculated in accordance with GAAP. See the tables above for reconciliations of GAAP to non-GAAP measures.

Radnostix, Inc. (formerly International Isotopes Inc.) Safe Harbor Statement:
Certain statements in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding the expected closing, timing and consideration of the DUF6 Sale; the receipt of NRC and other approvals; the value of any Nano Nuclear Energy Inc. common stock to be received; the timing of execution of Cobalt Products contracts and of NRC sealed source device amendments; recovery of Theranostics Products sales; FDA review of the Company's Drug Master File and close-out of recalls and inspection matters; supply of cobalt-57, gadolinium-153 and other radioisotopes and the clearing of backlog; commercialization timelines for Medical Devices products; start-up of the Company's second facility; and the Company's future growth expectations and liquidity. Information contained in such forward-looking statements is based on current expectations and is subject to change. These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance, or achievements of Radnostix, Inc. to be materially different from any future results, performance or achievements of the Company expressed or implied by these forward-looking statements, including the risk that the conditions to closing the DUF6 Sale are not satisfied and the DUF6 Sale does not close. Other factors, which could materially affect such forward-looking statements, can be found in the Company's filings with the Securities and Exchange Commission at www.sec.gov, including the risk factors in its Annual Report on Form 10-K for the year ended December 31, 2025 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. Investors, potential investors, and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are only made as of the date of this press release and Radnostix, Inc. undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Radnostix Contact:
ir@intisoid.com 
radnostix.com

Cision View original content:https://www.prnewswire.com/news-releases/radnostix-inc-reports-fy2026-3rd-quarter-and-nine-months-results--theranostics-sales-up-15-year-over-year-signs-agreement-to-sell-fluorine-productsduf6-assets-to-nano-nuclear-energy-submits-type-ii-dmf-for-sodium-iodide-i-1-302940744.html

SOURCE International Isotopes Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Radnostix INIS third-quarter 2026 financial results?

Radnostix reported $2,571,035 in revenue and a $842,242 net loss for the three months ended September 30, 2026. Revenue decreased 22% from $3,277,816, while net loss widened from $203,601. Theranostics growth was outweighed by lower Cobalt and Calibration & Reference sales.

What are the terms of Radnostix's Fluorine Products and DUF6 asset sale?

The agreement with Nano Nuclear Energy and its subsidiary HALEU Energy Fuel provides $13.5 million in consideration, comprising $9.5 million cash and $4 million in restricted NNE common shares. Closing requires NRC approval of the license transfer and NNE securing ownership or valid leasehold rights to the project site in Lea County, New Mexico.

What collateral and borrowing restrictions apply to Radnostix's new credit line?

Radnostix's $1.0 million revolving credit line with Bank of Commerce is secured by accounts receivable, inventory and equipment, with borrowing limits subject to eligible receivables and inventory. Entered into in October 2026, the facility has a 12-month term and bears interest at the prime rate.

What is the status of Radnostix's voluntary recalls and FDA inspection close-out?

Both voluntary recalls have been fully executed, but formal FDA recall close-out remains pending. Required documentation was submitted in June 2026. Radnostix also submitted a request to close out its April 2025 FDA Form 483 inspection.

Keep reading